title: Transarterial Chemoembolization of Giant Liver Haemangioma: A Multi-center Study with 836 Cases.
abstract: The purpose of the study is to evaluate the effectiveness and safety of transarterial chemoembolization (TACE) with pingyangmycin-lipiodol emulsion for the treatment of symptomatic giant hepatic haemangioma. Four hospitals (The Second Hospital of Shandong University, Qilu Hospital of Shandong University, Shandong Provincial Hospital and Jinan Municipal Hospital) participated in this study during 2002-2012. A total of 836 patients with symptomatic giant haemangioma were treated with pingyangmycin-lipiodol emulsion via selective TACE. The patients were followed-up for 12 months-10 years. The effectiveness of the treatment was evaluated by symptom assessments and upper abdominal magnetic resonance imaging or computed tomography. TACE was successfully performed for a total of 1120 lesions in 836 patients. Success rate of the procedure was 100 %. The mean diameter of the haemangiomas was significantly reduced after the interventional therapy (mean diameter 9.6 ± 0.8 vs. 3.6 ± 0.5 cm; P < 0.05). Symptom relief was achieved in all the patients during the follow-up period. No mortality was identified. TACE with pingyangmycin-lipiodol emulsion is a safe, feasible, and effective treatment for the giant symptomatic hepatic haemangioma.
authors.affiliation: Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, 250033, Shandong, China. dryuliangli@sina.com.|Tumor Interventional Institute of Shandong University, Jinan, China. dryuliangli@sina.com.
authors.forename: Yuliang
authors.initials: Y
authors.lastname: Li
authors.affiliation: Tumor Interventional Institute of Shandong University, Jinan, China.|Department of Interventional Medicine, The People's Hospital of Linzi District of Zibo City, Zibo, China.
authors.forename: Yunming
authors.initials: Y
authors.lastname: Jia
authors.affiliation: Tumor Interventional Institute of Shandong University, Jinan, China.|Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China.
authors.forename: Shengyong
authors.initials: S
authors.lastname: Li
authors.affiliation: Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, 250033, Shandong, China.|Tumor Interventional Institute of Shandong University, Jinan, China.
authors.forename: Wujie
authors.initials: W
authors.lastname: Wang
authors.affiliation: Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, 250033, Shandong, China.|Tumor Interventional Institute of Shandong University, Jinan, China.
authors.forename: Zhenting
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, 250033, Shandong, China.|Tumor Interventional Institute of Shandong University, Jinan, China.
authors.forename: Yongzheng
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, 250033, Shandong, China.|Tumor Interventional Institute of Shandong University, Jinan, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Liu
authors.affiliation: Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, 250033, Shandong, China.|Tumor Interventional Institute of Shandong University, Jinan, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.affiliation: Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, 250033, Shandong, China.|Tumor Interventional Institute of Shandong University, Jinan, China.
authors.forename: Haiyang
authors.initials: H
authors.lastname: Chang
authors.affiliation: Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, 250033, Shandong, China.|Tumor Interventional Institute of Shandong University, Jinan, China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D004998:Ethiodized Oil / Q000737:chemistry; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
chemical_list: D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; C025703:bleomycetin; D004998:Ethiodized Oil
keywords: Cavernous haemangioma; Iodized oil; Liver neoplasm; Pingyangmycin; Transarterial chemoembolization